Review



sfk inhibitor 200 nm pp2  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Millipore sfk inhibitor 200 nm pp2
    ( A and D ) Schematic of the experimental setups. ( B , E , and H ) Representative maximum intensity projections of pY1173-EGFR (B and E) or pSer1046/1047-EGFR (H) stainings in HeLa cells treated for 15 min with vehicle, 10 μM Yoda1, or EGF (10 ng/ml) with or without 30-min preincubations with 200 nM <t>PP2</t> (SFK inhibitor, B), or 10 μM SB202190 (p38 inhibitor, E). ( C and F ) Counts of pY1173-EGFR puncta per cell after the indicated treatments. Each symbol represents a cell, with n : vehicle, 1143; Yoda1, 717; EGF, 32; PP2, 1694; Yoda1 + PP2, 887; and EGF + PP2, 829; six experiments (C); vehicle, 867; Yoda1, 1125; EGF, 1544; SB, 948; Yoda1 + SB, 1358; and EGF + SB, 1016; three experiments (F). ( G ) Representative Western blots of pS1046/1047-EGFR. Vinculin used as loading control. ( I ) Counts of pSer1046/1047-EGFR puncta per cell after the indicated treatments. Each symbol represents an independent experiment ( N = 4), with ≥20 cells per picture and n = 4 pictures per experiment. ( J ) Manders colocalization coefficient for pSer1046/1047-EGFR and EEA1. Each symbol represents a picture ( n for each = vehicle, 13; Yoda1, 14; and EGF, 12), from N ≥ 4 independent experiments with ≥20 cells per picture. Scale bars, 20 μm. Error bars = median ± interquartile range. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 one-way ANOVA followed by Kruskal-Wallis post hoc test with Dunn’s correction for multiple comparisons.
    Sfk Inhibitor 200 Nm Pp2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sfk+inhibitor+200+nm+pp2/pmc10530101-115-20-21?v=Millipore
    Average 90 stars, based on 1 article reviews
    sfk inhibitor 200 nm pp2 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Piezo1 activates noncanonical EGFR endocytosis and signaling"

    Article Title: Piezo1 activates noncanonical EGFR endocytosis and signaling

    Journal: Science Advances

    doi: 10.1126/sciadv.adi1328

    ( A and D ) Schematic of the experimental setups. ( B , E , and H ) Representative maximum intensity projections of pY1173-EGFR (B and E) or pSer1046/1047-EGFR (H) stainings in HeLa cells treated for 15 min with vehicle, 10 μM Yoda1, or EGF (10 ng/ml) with or without 30-min preincubations with 200 nM PP2 (SFK inhibitor, B), or 10 μM SB202190 (p38 inhibitor, E). ( C and F ) Counts of pY1173-EGFR puncta per cell after the indicated treatments. Each symbol represents a cell, with n : vehicle, 1143; Yoda1, 717; EGF, 32; PP2, 1694; Yoda1 + PP2, 887; and EGF + PP2, 829; six experiments (C); vehicle, 867; Yoda1, 1125; EGF, 1544; SB, 948; Yoda1 + SB, 1358; and EGF + SB, 1016; three experiments (F). ( G ) Representative Western blots of pS1046/1047-EGFR. Vinculin used as loading control. ( I ) Counts of pSer1046/1047-EGFR puncta per cell after the indicated treatments. Each symbol represents an independent experiment ( N = 4), with ≥20 cells per picture and n = 4 pictures per experiment. ( J ) Manders colocalization coefficient for pSer1046/1047-EGFR and EEA1. Each symbol represents a picture ( n for each = vehicle, 13; Yoda1, 14; and EGF, 12), from N ≥ 4 independent experiments with ≥20 cells per picture. Scale bars, 20 μm. Error bars = median ± interquartile range. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 one-way ANOVA followed by Kruskal-Wallis post hoc test with Dunn’s correction for multiple comparisons.
    Figure Legend Snippet: ( A and D ) Schematic of the experimental setups. ( B , E , and H ) Representative maximum intensity projections of pY1173-EGFR (B and E) or pSer1046/1047-EGFR (H) stainings in HeLa cells treated for 15 min with vehicle, 10 μM Yoda1, or EGF (10 ng/ml) with or without 30-min preincubations with 200 nM PP2 (SFK inhibitor, B), or 10 μM SB202190 (p38 inhibitor, E). ( C and F ) Counts of pY1173-EGFR puncta per cell after the indicated treatments. Each symbol represents a cell, with n : vehicle, 1143; Yoda1, 717; EGF, 32; PP2, 1694; Yoda1 + PP2, 887; and EGF + PP2, 829; six experiments (C); vehicle, 867; Yoda1, 1125; EGF, 1544; SB, 948; Yoda1 + SB, 1358; and EGF + SB, 1016; three experiments (F). ( G ) Representative Western blots of pS1046/1047-EGFR. Vinculin used as loading control. ( I ) Counts of pSer1046/1047-EGFR puncta per cell after the indicated treatments. Each symbol represents an independent experiment ( N = 4), with ≥20 cells per picture and n = 4 pictures per experiment. ( J ) Manders colocalization coefficient for pSer1046/1047-EGFR and EEA1. Each symbol represents a picture ( n for each = vehicle, 13; Yoda1, 14; and EGF, 12), from N ≥ 4 independent experiments with ≥20 cells per picture. Scale bars, 20 μm. Error bars = median ± interquartile range. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 one-way ANOVA followed by Kruskal-Wallis post hoc test with Dunn’s correction for multiple comparisons.

    Techniques Used: Western Blot



    Similar Products

    sfk inhibitor 200 nm pp2  (Millipore)
    90
    Millipore sfk inhibitor 200 nm pp2
    ( A and D ) Schematic of the experimental setups. ( B , E , and H ) Representative maximum intensity projections of pY1173-EGFR (B and E) or pSer1046/1047-EGFR (H) stainings in HeLa cells treated for 15 min with vehicle, 10 μM Yoda1, or EGF (10 ng/ml) with or without 30-min preincubations with 200 nM <t>PP2</t> (SFK inhibitor, B), or 10 μM SB202190 (p38 inhibitor, E). ( C and F ) Counts of pY1173-EGFR puncta per cell after the indicated treatments. Each symbol represents a cell, with n : vehicle, 1143; Yoda1, 717; EGF, 32; PP2, 1694; Yoda1 + PP2, 887; and EGF + PP2, 829; six experiments (C); vehicle, 867; Yoda1, 1125; EGF, 1544; SB, 948; Yoda1 + SB, 1358; and EGF + SB, 1016; three experiments (F). ( G ) Representative Western blots of pS1046/1047-EGFR. Vinculin used as loading control. ( I ) Counts of pSer1046/1047-EGFR puncta per cell after the indicated treatments. Each symbol represents an independent experiment ( N = 4), with ≥20 cells per picture and n = 4 pictures per experiment. ( J ) Manders colocalization coefficient for pSer1046/1047-EGFR and EEA1. Each symbol represents a picture ( n for each = vehicle, 13; Yoda1, 14; and EGF, 12), from N ≥ 4 independent experiments with ≥20 cells per picture. Scale bars, 20 μm. Error bars = median ± interquartile range. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 one-way ANOVA followed by Kruskal-Wallis post hoc test with Dunn’s correction for multiple comparisons.
    Sfk Inhibitor 200 Nm Pp2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sfk+inhibitor+200+nm+pp2/pmc10530101-115-20-21?v=Millipore
    Average 90 stars, based on 1 article reviews
    sfk inhibitor 200 nm pp2 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A and D ) Schematic of the experimental setups. ( B , E , and H ) Representative maximum intensity projections of pY1173-EGFR (B and E) or pSer1046/1047-EGFR (H) stainings in HeLa cells treated for 15 min with vehicle, 10 μM Yoda1, or EGF (10 ng/ml) with or without 30-min preincubations with 200 nM PP2 (SFK inhibitor, B), or 10 μM SB202190 (p38 inhibitor, E). ( C and F ) Counts of pY1173-EGFR puncta per cell after the indicated treatments. Each symbol represents a cell, with n : vehicle, 1143; Yoda1, 717; EGF, 32; PP2, 1694; Yoda1 + PP2, 887; and EGF + PP2, 829; six experiments (C); vehicle, 867; Yoda1, 1125; EGF, 1544; SB, 948; Yoda1 + SB, 1358; and EGF + SB, 1016; three experiments (F). ( G ) Representative Western blots of pS1046/1047-EGFR. Vinculin used as loading control. ( I ) Counts of pSer1046/1047-EGFR puncta per cell after the indicated treatments. Each symbol represents an independent experiment ( N = 4), with ≥20 cells per picture and n = 4 pictures per experiment. ( J ) Manders colocalization coefficient for pSer1046/1047-EGFR and EEA1. Each symbol represents a picture ( n for each = vehicle, 13; Yoda1, 14; and EGF, 12), from N ≥ 4 independent experiments with ≥20 cells per picture. Scale bars, 20 μm. Error bars = median ± interquartile range. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 one-way ANOVA followed by Kruskal-Wallis post hoc test with Dunn’s correction for multiple comparisons.

    Journal: Science Advances

    Article Title: Piezo1 activates noncanonical EGFR endocytosis and signaling

    doi: 10.1126/sciadv.adi1328

    Figure Lengend Snippet: ( A and D ) Schematic of the experimental setups. ( B , E , and H ) Representative maximum intensity projections of pY1173-EGFR (B and E) or pSer1046/1047-EGFR (H) stainings in HeLa cells treated for 15 min with vehicle, 10 μM Yoda1, or EGF (10 ng/ml) with or without 30-min preincubations with 200 nM PP2 (SFK inhibitor, B), or 10 μM SB202190 (p38 inhibitor, E). ( C and F ) Counts of pY1173-EGFR puncta per cell after the indicated treatments. Each symbol represents a cell, with n : vehicle, 1143; Yoda1, 717; EGF, 32; PP2, 1694; Yoda1 + PP2, 887; and EGF + PP2, 829; six experiments (C); vehicle, 867; Yoda1, 1125; EGF, 1544; SB, 948; Yoda1 + SB, 1358; and EGF + SB, 1016; three experiments (F). ( G ) Representative Western blots of pS1046/1047-EGFR. Vinculin used as loading control. ( I ) Counts of pSer1046/1047-EGFR puncta per cell after the indicated treatments. Each symbol represents an independent experiment ( N = 4), with ≥20 cells per picture and n = 4 pictures per experiment. ( J ) Manders colocalization coefficient for pSer1046/1047-EGFR and EEA1. Each symbol represents a picture ( n for each = vehicle, 13; Yoda1, 14; and EGF, 12), from N ≥ 4 independent experiments with ≥20 cells per picture. Scale bars, 20 μm. Error bars = median ± interquartile range. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 one-way ANOVA followed by Kruskal-Wallis post hoc test with Dunn’s correction for multiple comparisons.

    Article Snippet: Experiments involving inhibitors included a 30-min pretreatment with EGFR kinase inhibitor 1 μM PD153035 (Sigma-Aldrich, SML0564), SFK inhibitor 200 nM PP2 (Sigma-Aldrich, P0042), or p38 inhibitor 10 μM SB202190 (Abcam, ab120638), all reconstituted in DMSO.

    Techniques: Western Blot